Evidence map›Paper›PMID 35707317›Full record

ArticleNeuro-oncology advances

Brain tumor patients and COVID-19 vaccines: results of an international survey.

Mathew R Voisin, Kathy Oliver, Stuart Farrimond, Tess Chee, Philip O'Halloran, Martin Glas, International Brain Tumour Alliance (IBTA) Senior Advisors, Gelareh Zadeh

Open access · goldAbstract read
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 4 countries.

Mathew R VoisinDivision of Neurosurgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0002-1191-9579
Kathy OliverInternational Brain Tumour Alliance (IBTA), Tadworth, UK.
Stuart FarrimondInternational Brain Tumour Alliance (IBTA), Tadworth, UK.
Tess CheeDepartment of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
Philip O'HalloranDepartment of Physiology and Medical Physics, Royal College of Surgeons in Ireland (RCSI), Dublin, Ireland.
Martin GlasDivision of Clinical Neurooncology, Department of Neurology and German Cancer Consortium (DKTK) Partner Site, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
International Brain Tumour Alliance (IBTA) Senior Advisors
Gelareh ZadehDivision of Neurosurgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0002-6637-4502
Brain Tumour Charity · GBUniversity of Toronto · CAGerman Cancer Society · DEMcMaster University · CARoyal College of Surgeons in Ireland · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: As the COVID-19 pandemic continues to unfold, the advent of multiple approved vaccines has led to a milestone in the fight against the virus. While vaccination rates and side effects are well established in the general population, these are largely unknown in patients with brain tumors. The purpose of this study was to determine if brain tumor patients and their caregivers have received a COVID-19 vaccine, and explore their thoughts and opinions on these vaccines. Methods: An anonymous 31-question online survey available in 8 languages was conducted from June 30, 2021 to August 31, 2021. The survey was open to adult brain tumor patients over the age of 18 and included both categorical and open-ended questions. Descriptive statistics and modified thematic analyses were performed for all questions as appropriate. Results: A total of 965 unique surveys were completed from 42 countries. The vast majority of both brain tumor patients and their caregivers have been vaccinated against COVID-19 (84.5% and 89.9%, respectively). No patient reported serious adverse events from any vaccine. Less than 10% of patients decided against receiving a vaccination against COVID-19, with the most common reason being concerns over the safety of the vaccine. Patients wanted more specific information on how COVID-19 vaccines might impact their future brain tumor treatment. Conclusions: In conclusion, the majority of brain tumor patients and their caregivers have received COVID-19 vaccines with no major side effects. Patients want more information on how COVID-19 vaccines might directly impact their brain tumor and future management.

Indexed as

brain tumorCOVID-19patientssurveyvaccine

Identifiers

PMID35707317
PMCPMC9129166
OpenAlexW4229026698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.